Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

You could have an underlying medical condition, such as nasal polyps. Also, it’s best to talk with a doctor if you have severe or concerning symptoms. They may want to perform tests to rule out ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been shown to reduce symptoms. Sanofi ...

Nasal microbiota transplantation could revolutionise the treatment of chronic rhinosinusitis and respiratory tract infections. Learn more!

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Symptoms: In mild cases, a child may complain about their ... Nasal growths: These growths include conditions such as nasal polyps, warts, and tumors. Long-lasting inflammation in the nose can lead to ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...